MITOMICS : a Multi-OMICS Approach for the Diagnosis of Mitochondrial Diseases
Study Details
Study Description
Brief Summary
MITOMICS aims to determine which RNA-Seq results (from muscle or fibroblasts) are the most informative for the interpretation of VUS identified by WES for patients suspected of mitochondrial myopathy. Analysis of RNA-Seq and WES results will performed with a computational approach using an autoencoder-based method
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
Mitochondrial diseases (MD) are rare, clinically and genetically extremely heterogeneous, caused by a deficit of energy production via the mitochondria. Mitochondria are dependent on 2 genomes mitochondrial DNA and nuclear DNA, and many pathogenic variants carried by these 2 genomes are responsible for mitochondrial diseases. The diagnostic strategies for MD patients have evolved significantly with the emergence of Next Generation Sequencing (NGS) also accelerating the identification of the responsible gene. However, the diagnostic yield remains limited and requires the development of new approaches. Previous studies showed that WES and RNA-Seq combination improves the diagnosis of MD, essentially by helping in the interpretation of identified VUS.
With MITOMICS project, we will included 66 patients suspected of a mitochondrial myopathy (clinical, histological or biochemical), with a negative mtDNA and WES NGS in trio. For each patient we will sequenced RNA from muscle and fibroblasts. Using a new innovative methology of multi-OMICS integration we will determined which RNA-Seq data (from muscle or fibroblasts) are the most informative for the interpretation of VUS identified by WES for patients suspected of mitochondrial myopathy. The results obtained will allow the interpretation of VUS and the identification of specific molecular signatures.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Mitochondrial diseases annalysing with methology of multi-OMICS integration we will determined which RNA-Seq data (from muscle or fibroblasts) are the most informative for the interpretation of VUS identified by WES for patients suspected of mitochondrial myopathy. |
Genetic: diagnosis of mitochondrial myopathy
• Determination of the presence of specific molecular signatures at the RNA level in muscles and fibroblasts from patients
|
Outcome Measures
Primary Outcome Measures
- number of variations interpreted as responsible for the Mitochondrial diseases [baseline]
• Comparison of the number of variations (splicing variant, expression level) or VUS, identified in WES, interpreted as responsible for the disease (class 4 or 5 variants) thanks to (i) the RNA-Seq carried out at from a muscle biopsy or (ii) RNA-Seq performed from fibroblasts
Secondary Outcome Measures
- RNA in mitochondiral deseases [baseline]
Patients for whom the RNA-Seq could not be performed and reason for failure
- variation of RNA in mitochondiral deseases [baseline]
Variations identified by RNA-Seq, allowing interpretation of WES data (splicing aberrants, monoallelic expressions, etc.)
- specific molecular signatures of mitochondiral deseases [baseline]
Determination of the presence of specific molecular signatures at the RNA level in muscles and fibroblasts from patients
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patients suspected of a mitochondrial disease with muscular signs (clinical, histological or biochemical)
-
Patients with negative mtDNA and WES NGS in trio
-
Patients with routine muscle and skin biopsies available
-
Blood samples from parents and / or relatives available for segregation studies
-
Informed consent of the study signed by the patient or the legal representatives of the minor patient or under guardianship
-
Patients affiliated to social security
Exclusion Criteria:
-
Patients with suspected mitochondrial disease without muscle involvement
-
Patients for whom the mtDNA NGS and WES have not been performed
-
Patients with suspected mitochondrial disease with causal variant identified
-
Refusal to sign the informed consent for the study
-
Insufficient amount of frozen material or culture failure for fibroblasts
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Centre Hospitalier Universitaire de Nice
Investigators
- Principal Investigator: BANNWARTH SYLVIE, Centre Hospitalier Universitaire de Nice
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 19-API-01
- 2020-A02651-38